Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
A 769662 (HB1351)
Description:Potent, reversible AMPK activator. Inhibits MSC proliferation.
Purity:>98%
A83-01 (HB3218)
Description:Selective TGF-βRI (ALK5), ALK4 and ALK7 inhibitor. Maintains human hiPSC self renewal, 3D growth matrix component and promotes long-term organoid growth. Aids fibroblast to NSC/cardiomyocyte reprogramming.
Purity:>98%
(+)-Abscisic acid (HB4674)
Description:Phytohormone and endogenous lanthionine synthetase C-like 2 (LANCL2) ligand
Purity:>99%
(±)-Anatoxin A fumarate (HB2023)
Description:Potent nicotinic agonist. Apoptosis inducer.
Purity:>99%
- Description:
Identifies early apoptotic, necrotic and viable cells